Skip to content

Bactec Mgit 960 Pza Kit

by Becton, Dickinson & CO 510(k)

Active United States

510(k) K021582

Overview

The BACTEC MGIT 960 PZA Kit is a susceptibility test powder for antimycobacterial agents, specifically designed for qualitative susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA). Classified as a susceptibility test powder under regulatory category 866.1640, this device aids in determining bacterial resistance, supporting targeted treatment decisions in microbiology laboratories. It operates within the BD BACTEC MGIT 960 System, a fully automated culture and susceptibility testing platform for mycobacteria.

This kit is supplied as a single-use reagent intended for use in clinical microbiology settings. It is not sterile but is intended for use with sterile culture media and patient samples. The device is regulated under FDA 510(k) clearance (K021582) as a Class II medical device, adhering to microbiology standards. Storage and handling follow manufacturer guidelines to maintain integrity, and its use is restricted to qualified laboratory personnel following established protocols for antimycobacterial susceptibility testing.

AI-generated from registry data, 1 Oct 2026.Not verified by deviCERTS or the manufacturer

Regulatory status

as of 28 Oct 2026

Recall ongoing. 2 ongoing FDA recalls. See recalls

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK021582 Date13 Jul 2002ClearedStatusActive

Coverage

1 jurisdiction

United States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not known
  • Not covered

United States — FDA 510(k) Active

Recalls

2 recalls · 2 ongoing · FDA

    • Ongoing Z-2023-2025 FDA Class II initiated 20 May 2025

    BD has received additional complaints of intermittent false resistance results for PZA during susceptibility testing of Mycobacterium tuberculosis isolates.

    • Ongoing Z-2686-2024 FDA Class II initiated 18 Jul 2024

    May intermittently produce falsely resistant results for pyrazinamide (PZA) during susceptibility testing of Mycobacterium tuberculosis isolates.

Specification

510(k)

510(k) Number
FDA Product Code
MJA
Device Class
Class II
Regulation
21 CFR Part 866.1640
Advisory Committee
Microbiology
FDA Decision
SESE Substantially Equivalent

Other devices from Becton, Dickinson & Co.

See all devices from Becton, Dickinson & Co. →

Questions

  • What is the BACTEC MGIT 960 PZA Kit used for?

    The BACTEC MGIT 960 PZA Kit is designed specifically for qualitative susceptibility testing of *Mycobacterium tuberculosis* to pyrazinamide (PZA). It helps microbiology laboratories determine whether the bacteria are resistant to PZA, which is critical for guiding targeted and effective treatment plans. This information supports clinical decisions by identifying strains that may require alternative or additional therapies.

  • Is the BACTEC MGIT 960 PZA Kit sterile?

    No, the BACTEC MGIT 960 PZA Kit is not sterile. It is intended for use with sterile culture media and patient samples within the BD BACTEC MGIT 960 System. The kit itself is a single-use reagent, and proper aseptic techniques must be followed when handling it to ensure reliable test results.

  • How is the BACTEC MGIT 960 PZA Kit supplied and used?

    The kit is supplied as a single-use reagent, meaning each kit is intended for one test cycle. It is not reusable and must be used within the BD BACTEC MGIT 960 automated system, which handles culture and susceptibility testing for mycobacteria. The kit is designed for clinical microbiology laboratories and requires qualified personnel to perform testing following established protocols.

  • Can the BACTEC MGIT 960 PZA Kit be reused?

    No, the BACTEC MGIT 960 PZA Kit is explicitly designed for single-use only. Reusing the kit could compromise test accuracy and introduce contamination risks, potentially leading to unreliable susceptibility results. Always follow the manufacturer’s guidelines for proper disposal after use.

  • What regulatory pathway does the BACTEC MGIT 960 PZA Kit follow?

    The BACTEC MGIT 960 PZA Kit is regulated under the FDA 510(k) clearance pathway as a Class II medical device, with clearance number K021582. It falls under regulatory category 866.1640 for susceptibility test powders and is classified as substantially equivalent to a predicate device. This ensures it meets microbiology standards for antimycobacterial testing.